Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

A preclinical overview of emerging therapeutic targets for glomerular diseases.

Cassis P, Zoja C, Perico L, Remuzzi G.

Expert Opin Ther Targets. 2019 Jul;23(7):593-606. doi: 10.1080/14728222.2019.1626827. Epub 2019 Jun 12.

PMID:
31150308
2.

Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome.

Buelli S, Zoja C, Remuzzi G, Morigi M.

Microorganisms. 2019 Jan 10;7(1). pii: E15. doi: 10.3390/microorganisms7010015. Review.

3.

Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease.

Rota C, Morigi M, Cerullo D, Introna M, Colpani O, Corna D, Capelli C, Rabelink TJ, Leuning DG, Rottoli D, Benigni A, Zoja C, Remuzzi G.

Stem Cell Res Ther. 2018 Aug 14;9(1):220. doi: 10.1186/s13287-018-0960-8.

4.

SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.

Cassis P, Locatelli M, Cerullo D, Corna D, Buelli S, Zanchi C, Villa S, Morigi M, Remuzzi G, Benigni A, Zoja C.

JCI Insight. 2018 Aug 9;3(15). pii: 98720. doi: 10.1172/jci.insight.98720. eCollection 2018 Aug 9.

5.

ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes.

Cassis P, Cerullo D, Zanchi C, Corna D, Lionetti V, Giordano F, Novelli R, Conti S, Casieri V, Matteucci M, Locatelli M, Taraboletti G, Villa S, Gastoldi S, Remuzzi G, Benigni A, Zoja C.

Diabetes. 2018 Oct;67(10):2069-2083. doi: 10.2337/db17-1508. Epub 2018 Jul 5.

6.

Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection.

Castiglioni L, Pignieri A, Fiaschè M, Giudici M, Crestani M, Mitro N, Abbate M, Zoja C, Rottoli D, Foray C, Fiordaliso F, Guerrini U, Tremoli E, Sironi L, Gelosa P.

J Hypertens. 2018 May;36(5):1129-1146. doi: 10.1097/HJH.0000000000001651.

PMID:
29278547
7.

Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.

Zoja C, Buelli S, Morigi M.

Pediatr Nephrol. 2019 Mar;34(3):379-388. doi: 10.1007/s00467-017-3850-x. Epub 2017 Dec 6. Review.

PMID:
29214442
8.

MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy.

Zanchi C, Macconi D, Trionfini P, Tomasoni S, Rottoli D, Locatelli M, Rudnicki M, Vandesompele J, Mestdagh P, Remuzzi G, Benigni A, Zoja C.

Diabetologia. 2017 Jun;60(6):1114-1125. doi: 10.1007/s00125-017-4248-9. Epub 2017 Mar 31.

9.

A previously unrecognized role of C3a in proteinuric progressive nephropathy.

Morigi M, Locatelli M, Rota C, Buelli S, Corna D, Rizzo P, Abbate M, Conti D, Perico L, Longaretti L, Benigni A, Zoja C, Remuzzi G.

Sci Rep. 2016 Jun 27;6:28445. doi: 10.1038/srep28445.

10.

Simplified Method to Measure Glomerular Filtration Rate by Iohexol Plasma Clearance in Conscious Rats.

Carrara F, Azzollini N, Nattino G, Corna D, Villa S, Cerullo D, Zoja C, Abrante B, Luis-Lima S, Porrini E, Cannata A, Ferrari S, Fois M, Stucchi N, Gaspari F.

Nephron. 2016;133(1):62-70. doi: 10.1159/000445843. Epub 2016 May 4.

PMID:
27160992
11.

Lipoprotein X Causes Renal Disease in LCAT Deficiency.

Ossoli A, Neufeld EB, Thacker SG, Vaisman B, Pryor M, Freeman LA, Brantner CA, Baranova I, Francone NO, Demosky SJ Jr, Vitali C, Locatelli M, Abbate M, Zoja C, Franceschini G, Calabresi L, Remaley AT.

PLoS One. 2016 Feb 26;11(2):e0150083. doi: 10.1371/journal.pone.0150083. eCollection 2016.

12.

Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy.

Zoja C, Locatelli M, Corna D, Villa S, Rottoli D, Nava V, Verde R, Piscitelli F, Di Marzo V, Fingerle J, Adam JM, Rothenhaeusler B, Ottaviani G, Bénardeau A, Abbate M, Remuzzi G, Benigni A.

Nephron. 2016;132(1):59-69. doi: 10.1159/000442679. Epub 2015 Dec 9.

PMID:
26646377
13.

B7-1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy.

Gagliardini E, Novelli R, Corna D, Zoja C, Ruggiero B, Benigni A, Remuzzi G.

J Am Soc Nephrol. 2016 Apr;27(4):999-1005. doi: 10.1681/ASN.2015030266. Epub 2015 Aug 28.

14.

Key pathways in renal disease progression of experimental diabetes.

Zoja C, Zanchi C, Benigni A.

Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv54-9. doi: 10.1093/ndt/gfv036. Review.

PMID:
26209738
15.

Mitochondrial-dependent Autoimmunity in Membranous Nephropathy of IgG4-related Disease.

Buelli S, Perico L, Galbusera M, Abbate M, Morigi M, Novelli R, Gagliardini E, Tentori C, Rottoli D, Sabadini E, Saito T, Kawano M, Saeki T, Zoja C, Remuzzi G, Benigni A.

EBioMedicine. 2015 Mar 6;2(5):456-66. doi: 10.1016/j.ebiom.2015.03.003. eCollection 2015 May.

16.

Et and diabetic nephropathy: preclinical and clinical studies.

Gagliardini E, Zoja C, Benigni A.

Semin Nephrol. 2015 Mar;35(2):188-96. doi: 10.1016/j.semnephrol.2015.03.003. Review.

PMID:
25966350
17.

Renal primordia activate kidney regenerative events in a rat model of progressive renal disease.

Imberti B, Corna D, Rizzo P, Xinaris C, Abbate M, Longaretti L, Cassis P, Benedetti V, Benigni A, Zoja C, Remuzzi G, Morigi M.

PLoS One. 2015 Mar 26;10(3):e0120235. doi: 10.1371/journal.pone.0120235. eCollection 2015.

18.

Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease.

Zoja C, Corna D, Locatelli M, Rottoli D, Pezzotta A, Morigi M, Zanchi C, Buelli S, Guglielmotti A, Perico N, Remuzzi A, Remuzzi G.

Nephron. 2015;129(1):52-61. doi: 10.1159/000369149. Epub 2014 Dec 17.

19.

Progression of renal injury toward interstitial inflammation and glomerular sclerosis is dependent on abnormal protein filtration.

Zoja C, Abbate M, Remuzzi G.

Nephrol Dial Transplant. 2015 May;30(5):706-12. doi: 10.1093/ndt/gfu261. Epub 2014 Aug 2. Review.

PMID:
25087196
20.

Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.

Locatelli M, Buelli S, Pezzotta A, Corna D, Perico L, Tomasoni S, Rottoli D, Rizzo P, Conti D, Thurman JM, Remuzzi G, Zoja C, Morigi M.

J Am Soc Nephrol. 2014 Aug;25(8):1786-98. doi: 10.1681/ASN.2013050450. Epub 2014 Feb 27.

21.

β-arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury.

Buelli S, Rosanò L, Gagliardini E, Corna D, Longaretti L, Pezzotta A, Perico L, Conti S, Rizzo P, Novelli R, Morigi M, Zoja C, Remuzzi G, Bagnato A, Benigni A.

J Am Soc Nephrol. 2014 Mar;25(3):523-33. doi: 10.1681/ASN.2013040362. Epub 2013 Dec 26.

22.

Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor.

Zanchi C, Locatelli M, Benigni A, Corna D, Tomasoni S, Rottoli D, Gaspari F, Remuzzi G, Zoja C.

PLoS One. 2013 Aug 14;8(8):e70775. doi: 10.1371/journal.pone.0070775. eCollection 2013.

23.

The Nrf2 pathway in the progression of renal disease.

Zoja C, Benigni A, Remuzzi G.

Nephrol Dial Transplant. 2014 Feb;29 Suppl 1:i19-i24. doi: 10.1093/ndt/gft224. Epub 2013 Jun 11. Review.

PMID:
23761459
24.

Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathway.

Gagliardini E, Perico N, Rizzo P, Buelli S, Longaretti L, Perico L, Tomasoni S, Zoja C, Macconi D, Morigi M, Remuzzi G, Benigni A.

Am J Pathol. 2013 Jul;183(1):119-30. doi: 10.1016/j.ajpath.2013.03.025. Epub 2013 May 23.

25.

Evaluation of the Zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles.

Siwy J, Zoja C, Klein J, Benigni A, Mullen W, Mayer B, Mischak H, Jankowski J, Stevens R, Vlahou A, Kossida S, Perco P, Bahlmann FH.

PLoS One. 2012;7(12):e51334. doi: 10.1371/journal.pone.0051334. Epub 2012 Dec 7.

26.

Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects.

Zoja C, Corna D, Nava V, Locatelli M, Abbate M, Gaspari F, Carrara F, Sangalli F, Remuzzi G, Benigni A.

Am J Physiol Renal Physiol. 2013 Mar 15;304(6):F808-19. doi: 10.1152/ajprenal.00376.2012. Epub 2012 Nov 7.

27.

Increased renal versican expression is associated with progression of chronic kidney disease.

Rudnicki M, Perco P, Neuwirt H, Noppert SJ, Leierer J, Sunzenauer J, Eder S, Zoja C, Eller K, Rosenkranz AR, Müller GA, Mayer B, Mayer G.

PLoS One. 2012;7(9):e44891. Epub 2012 Sep 14.

28.

Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy.

Zoja C, Garcia PB, Rota C, Conti S, Gagliardini E, Corna D, Zanchi C, Bigini P, Benigni A, Remuzzi G, Morigi M.

Am J Physiol Renal Physiol. 2012 Nov 1;303(9):F1370-81. doi: 10.1152/ajprenal.00057.2012. Epub 2012 Sep 5.

29.

Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice.

Zoja C, Locatelli M, Pagani C, Corna D, Zanchi C, Isermann B, Remuzzi G, Conway EM, Noris M.

J Immunol. 2012 Oct 1;189(7):3661-8. Epub 2012 Aug 31.

30.

Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes.

Zoja C, Cattaneo S, Fiordaliso F, Lionetti V, Zambelli V, Salio M, Corna D, Pagani C, Rottoli D, Bisighini C, Remuzzi G, Benigni A.

Am J Physiol Renal Physiol. 2011 Nov;301(5):F1114-23. doi: 10.1152/ajprenal.00122.2011. Epub 2011 Aug 3.

31.

Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.

Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C.

J Immunol. 2011 Jul 1;187(1):172-80. doi: 10.4049/jimmunol.1100491. Epub 2011 Jun 3.

32.

Effect of ACE inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model.

Sangalli F, Carrara F, Gaspari F, Corna D, Zoja C, Botti L, Remuzzi G, Remuzzi A.

Am J Physiol Renal Physiol. 2011 Jun;300(6):F1291-300. doi: 10.1152/ajprenal.00656.2010. Epub 2011 Mar 30.

33.

Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.

Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G.

Am J Physiol Renal Physiol. 2010 Nov;299(5):F1203-11. doi: 10.1152/ajprenal.00045.2010. Epub 2010 Aug 18.

34.

Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction.

Zoja C, Buelli S, Morigi M.

Pediatr Nephrol. 2010 Nov;25(11):2231-40. doi: 10.1007/s00467-010-1522-1. Epub 2010 Apr 28. Review.

PMID:
20424866
35.

Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury.

Morigi M, Rota C, Montemurro T, Montelatici E, Lo Cicero V, Imberti B, Abbate M, Zoja C, Cassis P, Longaretti L, Rebulla P, Introna M, Capelli C, Benigni A, Remuzzi G, Lazzari L.

Stem Cells. 2010 Mar 31;28(3):513-22. doi: 10.1002/stem.293.

36.

Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes.

Gagliardini E, Corna D, Zoja C, Sangalli F, Carrara F, Rossi M, Conti S, Rottoli D, Longaretti L, Remuzzi A, Remuzzi G, Benigni A.

Am J Physiol Renal Physiol. 2009 Nov;297(5):F1448-56. doi: 10.1152/ajprenal.00340.2009. Epub 2009 Aug 12.

37.

V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.

Perico N, Zoja C, Corna D, Rottoli D, Gaspari F, Haskell L, Remuzzi G.

Kidney Int. 2009 Nov;76(9):960-7. doi: 10.1038/ki.2009.267. Epub 2009 Jul 22.

38.

Thrombomodulin mutations in atypical hemolytic-uremic syndrome.

Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM.

N Engl J Med. 2009 Jul 23;361(4):345-57. doi: 10.1056/NEJMoa0810739.

39.

The role of chemokines in progressive renal disease.

Zoja C, Garcia PB, Remuzzi G.

Front Biosci (Landmark Ed). 2009 Jan 1;14:1815-22. Review.

PMID:
19273165
40.

Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells.

Buelli S, Abbate M, Morigi M, Moioli D, Zanchi C, Noris M, Zoja C, Pusey CD, Zipfel PF, Remuzzi G.

Kidney Int. 2009 May;75(10):1050-9. doi: 10.1038/ki.2009.8. Epub 2009 Feb 25.

41.

Disruption of the Ang II type 1 receptor promotes longevity in mice.

Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM, Remuzzi G.

J Clin Invest. 2009 Mar;119(3):524-30. doi: 10.1172/JCI36703. Epub 2009 Feb 9.

42.

Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides.

Macconi D, Chiabrando C, Schiarea S, Aiello S, Cassis L, Gagliardini E, Noris M, Buelli S, Zoja C, Corna D, Mele C, Fanelli R, Remuzzi G, Benigni A.

J Am Soc Nephrol. 2009 Jan;20(1):123-30. doi: 10.1681/ASN.2007111233. Epub 2008 Dec 17.

43.

Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin.

Zanchi C, Zoja C, Morigi M, Valsecchi F, Liu XY, Rottoli D, Locatelli M, Buelli S, Pezzotta A, Mapelli P, Geelen J, Remuzzi G, Hawiger J.

J Immunol. 2008 Jul 15;181(2):1460-9.

44.

Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice.

Morigi M, Introna M, Imberti B, Corna D, Abbate M, Rota C, Rottoli D, Benigni A, Perico N, Zoja C, Rambaldi A, Remuzzi A, Remuzzi G.

Stem Cells. 2008 Aug;26(8):2075-82. doi: 10.1634/stemcells.2007-0795. Epub 2008 May 22.

45.

Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury.

Abbate M, Zoja C, Corna D, Rottoli D, Zanchi C, Azzollini N, Tomasoni S, Berlingeri S, Noris M, Morigi M, Remuzzi G.

J Am Soc Nephrol. 2008 Jun;19(6):1158-67. doi: 10.1681/ASN.2007060686. Epub 2008 Mar 19.

46.

Insulin-like growth factor-1 sustains stem cell mediated renal repair.

Imberti B, Morigi M, Tomasoni S, Rota C, Corna D, Longaretti L, Rottoli D, Valsecchi F, Benigni A, Wang J, Abbate M, Zoja C, Remuzzi G.

J Am Soc Nephrol. 2007 Nov;18(11):2921-8. Epub 2007 Oct 17.

47.

Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation.

Corna D, Sangalli F, Cattaneo D, Carrara F, Gaspari F, Remuzzi A, Zoja C, Benigni A, Perico N, Remuzzi G.

Am J Nephrol. 2007;27(6):630-8. Epub 2007 Sep 11.

PMID:
17851231
48.

Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus.

Zoja C, Casiraghi F, Conti S, Corna D, Rottoli D, Cavinato RA, Remuzzi G, Benigni A.

Arthritis Rheum. 2007 May;56(5):1629-37.

49.

Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus.

Benigni A, Caroli C, Longaretti L, Gagliardini E, Zoja C, Galbusera M, Moioli D, Romagnani P, Tincani A, Andreoli L, Remuzzi G.

Arthritis Rheum. 2007 May;56(5):1569-78.

50.

Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats.

Gianella A, Nobili E, Abbate M, Zoja C, Gelosa P, Mussoni L, Bellosta S, Canavesi M, Rottoli D, Guerrini U, Brioschi M, Banfi C, Tremoli E, Remuzzi G, Sironi L.

Am J Pathol. 2007 Apr;170(4):1165-77.

Supplemental Content

Support Center